| http://www.w3.org/ns/prov#value | - We incurred capital expenditures of $30.4 million in the second quarter, with the majority of the capital focused on new product and expansion activities, mostly for our Pharma Systems, North America, Europe and Asia capacity expansion, and our IP initiatives.
|
